Skip to content

Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women

Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women:a Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05570331
Enrollment
2200
Registered
2022-10-06
Start date
2022-01-01
Completion date
2025-12-31
Last updated
2022-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer, HPV Infection

Keywords

Cervical cancer screening, HPV test, HPV integration

Brief summary

The American Society for Colposcopy and Cervical Pathology (ASCCP) recommended HPV testing or co-cytology testing as the standard primary approach for cervical cancer (CC) screening, which is highly sensitive for detection of cervical intraepithelial neoplasia grade 3 or worse. However, in clinical CC screening practice, the specificity and positive predictive value of the ASCCP-recommended strategy is relatively low, which leads to excessive colposcopy and common overtreatment, especially in China with a large number of cervical cancer cases. HPV integration in the host genome is a critical step in cervical carcinogenesis and is highly specific for detection of cervical cancer. Whether HPV integration analysis can play a role in the triage of cervical cancer screening has not yet been investigated.

Detailed description

Based on the dilemma of the cervical cancer screening process, in the last five years, our team developed a novel cervical cancer triage strategy and conducted a large cohort study, which evaluated the clinical performance of HPV integration triage alone and in combination with HPV16/18 or HPV16 genotyping of HPV-positive women. We found that the specificity of HPV integration for greater than cervical intraepithelial neoplasia 3 was 94.5%, which was significantly higher than that of cytology (63.8%; P \< 0.001) in our previous retrospective study.Here, we conducted a large prospective cohort study evaluating the clinical performance of HPV integration triage of HPV-positive women.

Interventions

DIAGNOSTIC_TESTHPV integration test

HPV-positive patients who are eligible for cervical cancer screening will be asked to collect Cervical Exfoliated Cells sample for the HPV integration screening test and for the HPV testing and TCT.

Sponsors

Ding Ma
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Consenting women aged 20y-70y with HPV-positive results

Exclusion criteria

* Not providing informed consent * previously confirmed CIN, cervical cancer, or other malignancies * previous therapeutic procedure to cervix * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Risk of CIN2+ disease3 yearsCIN2+ diagnosed on biopsy obtained at colposcopy.
Risk of CIN3+ disease3 yearsCIN3+ diagnosed on biopsy obtained at colposcopy.

Countries

China

Contacts

Primary ContactTing Hu, MD, PhD
cat_huting@163.com862783662681

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026